Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday reported fourth-quarter adjusted earnings of $2.42 per share, beating the consensus of $2.36.
The provider of diagnostic information services reported sales of $2.81 billion, up 7.1% year over year, beating the consensus of $2.75 billion. Consolidated organic revenues grew by 6.4%.
“We closed 2025 with a strong fourth quarter, and delivered double-digit growth in revenues and earnings per share for the full year,” said Jim Davis, Chairman, CEO, and President. “Our robust performance demonstrates continued execution of our strategy to deliver category-defining clinical innovations that fulfill customers’ needs and to form strategic collaborations supporting growth.”
Operating income increased 7% to $386 million. Adjusted operating income was $429 million, or a margin of 15.3% compared to $409 million, or 15.6% of revenues, last year.
Total volume, measured …